A practical reference on nuclear receptor: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-06-10 and is reviewed periodically as new material appears.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Visual inspection is not sufficient for identity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water; stock solutions use organic solvent. |
| Storage | -20°C, desiccated, protected from light | Limits hydrolysis and photodegradation. |
| Analytical method | HPLC-UV/MS | Used for identity and purity assessment. |
| Synonyms | SR9009, Stenabolic | Naming varies by supplier. |
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
Validation and Quality Control: It is important to ensure the accuracy and reliability of the integration process, by performing validation and quality control checks to the software itself. This may involve comparing integration results with known standards, replicating analyses, and assessing precision and accuracy Applications are also available for simulation of chromatography, for example for teaching, demonstration, or for method development &/or optimization.
There are many challenges surrounding human remains accessioned by museums, including legal complications involved in dealing with human remains, involvement of living relatives or tribes, and potential repatriation and issues such as the Native American Graves Protection and Repatriation Act of 1990 (NAGPRA). NAGPRA requires any federal or federally-funded institution, with the exception of the Smithsonian Institution, to submit full inventories of their Native American funerary and sacred objects and human remains and to repatriate these objects to their tribe of origin should a request be made to do so. Should a museum possess human remains which have a direct living relative or group (Native American or otherwise), it is their ethical obligation to involve these individuals in the care and treatment of the remains. Acquisition of human remains by museums can happen in a number of ways, some of which are considered to be unethical today. Many museums have human remains in their collections which have been there for over a hundred years, in which case they may likely have been acquired in ethically or morally unsound ways. This has led to growing concerns that the display of human remains has become depersonalised, by continuing to keep them in collections. Most institutions and museum associations have their own policies on the acquisition of human remains. Some guidelines for the care of human remains including acceptable means of acquisition can be found below.
Newsom supports a series of tentative water-sharing agreements that would bring an end to the dispute between farmers, cities, fishers, and environmentalists over how much water should be left in the state's two most important rivers, the Sacramento and San Joaquin, which flow into the Delta.
Sources: en.wikipedia.org
Between the 2023 and 2026 elections, Thailand had three prime ministers from two parties succeed each other. Srettha Thavisin lasted 358 days but was dismissed by the Constitutional Court on 14 August 2024 over his appointment of Pichit Chuenban to his cabinet. He was succeeded by Paetongtarn Shinawatra from Pheu Thai who was prime minister for little over a year but was suspended on 1 July 2025. Following a skirmish between Thai and Cambodian soldiers on 28 May 2025, a border crisis and conflict ensued between the two countries leading to a political crisis. A controversial phone call held between Paetongtarn and Cambodian Senate President Hun Sen was leaked in June, leading to the withdrawal of Bhumjaithai from the coalition and her suspension as PM. The Constitutional Court removed her as prime minister on 29 August. Paetongtarn is the daughter of former prime minister Thaksin Shinawatra who returned to Thailand in 2023 after 15-years in exile on the same day Srettha became prime minister. Controversially, Thaksin did not spend a complete day in prison as he was transferred to the Police General Hospital; he was later released on parole on 13 January 2024. During both Srettha and Paetongtarn's premierships, Thaksin was routinely accused of being the 'power behind the throne'. On 9 September 2025, in the 14th floor case, Thaksin was sentenced to a year in prison by the Supreme Court. Following the removal of Paetongtarn, both Pheu Thai and Bhumjaithai sought the support of the People's Party to back their candidates.
The mean lifetime of 238U (or any nuclide) is the half-life divided by ln(2) ≈ 0.693 (or multiplied by 1/ln(2) ≈ 1.443), which is about 2×1017 seconds, so 1 mole of 238U emits 3×106 alpha particles per second, producing the same number of thorium-234 atoms. In a closed system an equilibrium would be reached in which all members except the stable end-product have fixed ratios to one another, but in slowly decreasing amount. The amount of 206Pb will increase accordingly while that of 238U decreases; all steps in the decay chain have this same rate of 3×106 decayed particles per second per mole 238U. While 238U is minimally radioactive, its decay products, thorium-234 and protactinium-234, are beta particle emitters with half-lives of about 20 days and one minute respectively. Protactinium-234 decays to uranium-234, which has a half-life of hundreds of millennia, and this isotope does not reach an equilibrium concentration for a very long time. When the two first isotopes in the decay chain reach their relatively small equilibrium concentrations, a sample of initially pure 238U will emit three times the radiation due to 238U itself, and most of this radiation is beta particles. As already touched upon above, when starting with pure 238U, within a human timescale the equilibrium applies for the first three steps in the decay chain only. Thus, for one mole of 238U, 3×106 times per second one alpha and two beta particles and a gamma ray are produced, together 6.7 MeV, for a rate of 3 μW.
In 2009, more than 18,000 votes were cast in a BBC poll to find the UK's favourite poet; Thomas was placed 10th. Several of his poems have passed into the cultural mainstream, and his work has been used by authors, musicians and film and television writers. The BBC Radio programme Desert Island Discs, in which guests usually choose their favourite songs, has heard 50 participants select a Dylan Thomas recording. John Goodby states that this popularity with the reading public allows Thomas's work to be classed as vulgar and common. Goodby also cites that, despite a brief period during the 1960s when Thomas was considered a cultural icon, the poet has been marginalized in critical circles due to his exuberance, in both life and work, and his refusal to know his place. Goodby believes that Thomas has been mainly snubbed since the 1970s and has become "... an embarrassment to twentieth-century poetry criticism", his work failing to fit standard narratives and thus being ignored rather than studied. In June 2022, Thomas was the subject of BBC Radio 4's In Our Time.
The Port of Holyhead is a busy ferry port. Stena Line, Northern Europe's biggest ferry company, operates from the port, as do Irish Ferries. Ferries sail to Dublin. Holyhead railway station is the terminus of the North Wales Coast Line and is currently served by Avanti West Coast and Transport for Wales services. Avanti West Coast runs direct trains to London Euston via Crewe and Transport for Wales operate direct trains to Cardiff and Birmingham International, via Wrexham and Shrewsbury; they also operate on the route to Manchester Piccadilly, via Warrington.
Sources: en.wikipedia.org
=== Liver fibrosis === TGF-β1 has been implicated in the process of activating hepatic stellate cells (HSCs) with the magnitude of hepatic fibrosis being in proportion to increase in TGF-β levels. Studies have shown that ACTA2 is associated with TGF-β pathway that enhances contractile properties of HSCs leading to liver fibrosis.
FOP is an autosomal dominant disorder. Thus, a child of an affected heterozygous parent and an unaffected parent has a 50% probability of being affected. Two affected individuals can produce unaffected children. Two unaffected individuals can produce an affected offspring as a result of the mutation of the gene. The homozygous dominant form is more severe than the heterozygous form. The protein that causes ossification is normally deactivated by an inhibitory protein after a fetus's bones are formed in the womb, but in patients with FOP, the protein keeps working. Aberrant bone formation in patients with FOP occurs when injured connective tissue or muscle cells at the sites of injury or growth incorrectly express an enzyme for bone repair during apoptosis (self-regulated cell death), resulting in lymphocytes containing excess bone morphogenetic protein 4 (BMP4) provided during the immune system response. The bone that results occurs independently of the normal skeleton, forming its own discrete skeletal elements. These elements, however, can fuse with normal skeletal bone. The diaphragm, tongue, and extra-ocular muscles are spared in this process, as well as cardiac and smooth muscle. Since the incorrect enzyme remains unresolved within the immune response, the body continues providing the incorrect BMP4-containing lymphocytes. BMP4 is a product that contributes to the development of the skeleton in the normal embryo. The ACVR1 gene encodes a bone morphogenic protein (BMP) receptor; this gene is mutated in FOP.
== Interactions == Collagen, type VII, alpha 1 forms a complex network with several other proteins in the basement membrane. It has been shown to interact with laminin 5 and fibronectin, as well as collagen IV, by binding these proteins in the NC-1 domain. The stability of the basement membrane and dermal-epidermal junction is thought to be due to these interactions.
Sources: en.wikipedia.org
Liquid chromatography with mass spectrometry is a common approach. Ultraviolet detection and nuclear magnetic resonance can support identification when suitable standards are available.
The solid is generally kept cold, dry, and protected from light. Solutions are often frozen in single-use aliquots to reduce repeated freeze-thaw cycles.
It indicates a material sold for laboratory study, not for human use. The label does not guarantee pharmaceutical purity, sterility, or regulatory approval.
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.